Arsh et al., 2024

medicine
Author

Arsh et al.

Year of Publication

2024

Journal

Annals of Medicine & Surgery

ISSN

2049-0801

Publisher

Wolters Kluwer (London, United Kingdom)

Indexing

PubMed Central, Web of Science, Scopus (discontinued)

Erratum

Corrigendum (September 4, 2024)

Using PCSK9 inhibition as a therapeutic approach for COVID-19 presents several challenges and potential limitations. As of my last knowledge update in September 2023, clinical data supporting its use were limited.1

Eight months after the original publication of the article, an erratum was published, acknowledging that “the authors omitted to declare their use of AI tools”.2 According to the authors, the tools used were Grammarly and QuillBot. The AI-generated text has not been redacted from the original article.

gantt
  dateFormat YYYY-MM-DD
  axisFormat %b %Y
  todayMarker off
  
  Article published : milestone,2024-01-03,2024-01-03
  AcAI contacts journal : milestone,2024-03-19,2024-03-19
  Editor-in-Chief response—will investigate : milestone,2024-03-20,2024-03-20
  Update—authors confirm use of AI tools, erratum to be published : milestone,2024-03-21,2024-03-21
  AcAI request for update : milestone,2024-04-30,2024-04-30
Journal response—erratum being prepared for next available issue : milestone,2024-04-30
  AcAI request for update : milestone,2024-08-12
Journal response—erratum being prepared for next available issue : milestone,2024-08-13
Erratum published : milestone,2024-09-04
Figure 1: Timeline of correspondence between Academ-AI and the journal.

References

1Arsh H, Manoj Kumar FNU, Simran FNU, et al. Role of PCSK9 inhibition during the inflammatory stage of SARS-COV-2: an updated review. Annals of Medicine and Surgery. 2024;86(2):899-908. doi:10.1097/MS9.0000000000001601
2Role of PCSK9 inhibition during the inflammatory stage of SARS-COV-2: an updated review: Erratum. Annals of Medicine and Surgery. 2024;86(9):5659. doi:10.1097/MS9.0000000000002497